Saint Louis University School of Law

Scholarship Commons
All Faculty Scholarship

2016

Missing the “Target”: Preventing the Unjust
Inclusion of Vulnerable Children for Medical
Research Studies
Ruqaiijah A. Yearby
Saint Louis University School of Law

Follow this and additional works at: https://scholarship.law.slu.edu/faculty
Part of the Civil Rights and Discrimination Commons, Health Law and Policy Commons, and
the Medical Jurisprudence Commons
Recommended Citation
Yearby, Ruqaiijah A., "Missing the “Target”: Preventing the Unjust Inclusion of Vulnerable Children for Medical Research Studies"
(2016). All Faculty Scholarship. 83.
https://scholarship.law.slu.edu/faculty/83

This Article is brought to you for free and open access by Scholarship Commons. It has been accepted for inclusion in All Faculty Scholarship by an
authorized administrator of Scholarship Commons. For more information, please contact erika.cohn@slu.edu, ingah.daviscrawford@slu.edu.

American Journal of Law & Medicine, 42 (2016): 797-833
American Society of Law & Medical Ethics, © 2016 The Author(s)
Boston University School of Law
DOI: 10.1177/0098858817701961

MISSING THE “TARGET”:
PREVENTING THE UNJUST
INCLUSION OF VULNERABLE
CHILDREN FOR MEDICAL
RESEARCH STUDIES
Ruqaiijah Yearby†

I. INTRODUCTION
Nearly everyone has experienced a burn and the resulting pain. Now imagine that
you suffer a third-degree radiation burn that injures all the layers of your skin as well
as the tissue, causing you extreme pain. . The burn turns your skin white, cherry red, or
black and may produce blisters that are dry, hard, and leathery-looking. The burn can
also be seen on the surface of your lungs and gastrointestinal tract. If the burn is big
enough you will need skin grafts and surgery to replace the skin and tissue that will
never grow back, as well as treatment to prevent infection. Assumedly, no human
being would intentionally cause another human being to experience this type of pain
and suffering. However, U.S. researchers did. Researchers at the Medical College of
Virginia conducted radiation tests on healthy African American children, as young as 6
months old, deliberately causing third-degree burns to their skin.1 The tests not only
damaged the skin of these children, causing them extreme pain, but it also required
surgery and skin grafts.2
Although the central purpose of medical research on children is to “generate new
knowledge” that can improve children’s health, research “can never take precedence

†
Oliver C. Schroeder Jr. Distinguished Research Scholar and Professor of Law, Case Western Reserve
University, School of Law, B.A. (Honors Biology), University of Michigan, 1996; J.D., Georgetown
University Law Center, 2000; M.P.H., Johns Hopkins School of Public Health, 2000. I would like to thank
Ifeoma Ajunwa, Deleso Alford, Ayesha Bell Hardaway, Devonya Havis, Cynthia Ho, Laura McNallyLevine, Teresa Miller, Rebecca Redwood, and L. Song Richardson for their insightful comments.
Additionally, I would also like to thank my outstanding research assistants, Samantha Malusky, Nadia
Chaudhry, Maureen Polen, and Di Zhang. A draft of this paper was presented at the Oxford Global Health
and Bioethics International Conference in Oxford, England and the Lutie A. Lytle Black Female Faculty
Writing Workshop.
1
HARRIET WASHINGTON, MEDICAL APARTHEID 236-37 (2007) (discussing a Medical College of
Virginia experiment to determine “whether radiation inflicted different degrees of damage on the skins of
black people than on that of whites”).
2
See id.
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over the rights and interests of” children serving as research subjects.3 Unfortunately,
medical research has too often taken precedence over the rights and interests of
children, which is why many researchers and bioethicists have characterized the
history of medical research on children as a history of child abuse.4 Usually, the debate
regarding the use of children in medical research studies has centered on questions
regarding the ethical principles of autonomy (informed consent)5 and beneficence (the
best interest of the child based on a benefit risk analysis).6 The debate has rarely
focused on the justice principle.7
My article begins to fill this void by critically analyzing medical research studies
conducted on children by discussing the requirements of the justice principle. The
justice principle, used to determine who will serve as a research subject,8 is the most
significant ethical principle governing medical research studies because the first thing
that researchers must consider when designing their study is subject selection. Once it
is decided who will serve as a research subject, the researcher can determine whether
the study complies with the requirements of autonomy and beneficence.
When selecting research subjects, the justice principle prohibits targeting.
Targeting is the systematic selection of research subjects who are from vulnerable
populations, such as racial minorities, children, and the economically disadvantaged,
“because of their easy availability, their compromised position, or their manipulability,
rather than for reasons directly related to the problem being studied.”9 Additionally,
even if the research is directly related to a condition suffered by the vulnerable
population, researchers should not use these populations as research subjects if they
are already overburdened due to lack of access to essential goods, such as food and
housing. Consequently, research subjects should be chosen according to an order of
3
Declaration of Helsinki, WORLD MED. ASS’N (2016), http://www.wma.net/en/30publications/
10policies/b3/ [http://perma.cc/HNL2-JSZ9] (last amended in October 2013).
4
Susan E. Lederer & Michael A. Grodin, Historical Overview: Pediatric Experimentation, in
CHILDREN AS RESEARCH SUBJECTS: SCIENCE, ETHICS, AND LAW 18-19 (Michael A. Grodin & Leonard H.
Glantz eds., 1994).
5
45 C.F.R. § 46.408 (2015). For a detailed discussion regarding the balance between the need for
medical research studies on children and the need for informed consent, see Additional Protections for
Children Involved as Subjects in Research, 48 Fed. Reg. 9814 (Mar. 8, 1983); Fed. Reg. 31,786 (July 21,
1978); National Institutes of HEALTH, NIH Policy And Guidelines On The Inclusion Of Children As
Participants In Research Involving Human Subjects (Mar. 6, 1998), http://grants.nih.gov/
grants/guide/notice-files/not98-024.html [https://perma.cc/53WP-LVQZ]; NAT'L COMM'N FOR THE
PROTECTION OF HUMAN SUBJECTS OF BIOMEDICAL & BEHAV. RES., PUBL’N NO. (OS) 77-0004, REPORT
AND RECOMMENDATIONS: RESEARCH INVOLVING CHILDREN, PASSIM (1977). Paul Ramsey and Richard
McCormick provided the most influential discussion regarding 2 (arguing that “any non-therapeutic research
on children was absolutely unethical—even with parental approval”); Richard A. McCormick,
Experimentation in Children: Sharing in Sociality, 6 HASTING CTR. REP. 41, 42 (1976) (arguing that
children may participate in medical research studies with parental consent if it would benefit the child and is
a “reasonable presumption of the child’s wishes”).
6
45 C.F.R. §§ 46.404-46.407 (2010); NAT’L INSTS. OF HEALTH, supra note 5; NAT'L COMM'N FOR THE
PROTECTION OF HUMAN SUBJECTS OF BIOMEDICAL & BEHAV. RES., supra note 5. See also, Loretta
Kopelman, Children as Research Subjects: Moral Disputes, Regulatory Guidance, and Recent Court
Decisions, 73 MOUNT SINAI J. MED. 596 (2006); Michelle Oberman & Joel Frader, Dying Children and
Medical Research: Access to Clinical Trials as Benefit and Burden, 29 AM. J.L. & MED. 301 (2003).
7
45 C.F.R. § 46.111(a)(3) (2015) (prohibiting targeting children for use in medical research studies).
8
The Belmont Report, 76 Fed. Reg. 23,192, 23,194 (Apr. 18, 1979).
9
Id. The justice principle also requires that if vulnerable populations are used in medical research
studies then the benefits of the research must be distributed to those vulnerable populations. See id. I discuss
the justice principle’s requirement that the populations that participate in medical research studies must be
the populations that benefit from the research in my forthcoming article entitled, Exploitation in Medical
Research Forty Years After the Tuskegee Syphilis Study, 67 CASE W. RES. UNIV. L. REV. (2017)
(forthcoming).
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preference of subjects for research: the economically advantaged before the
economically disadvantaged, the majority before minorities, and adults before
children.
Notwithstanding the Justice Principle, researchers continue to target children for
medical research studies. Since the late 1700s, children have repeatedly been targeted
for participation in medical research studies because they were readily accessible and
easy to manipulate.10 Using economically disadvantaged minority children as an
example of the harm all children suffer when targeted for medical research studies, I
argue that the justice principle must be redefined and new safeguards must be
implemented to protect all child participants. Specifically, Section II provides a
descriptive overview of the purpose and structure of medical research studies, as well
as a brief history of medical research studies that targeted economically disadvantaged
minority children. Section III examines the parameters of the justice principle and
further defines what constitutes targeting. Section IV discusses the problems with the
enforcement of the justice principle and provides examples of medical research studies
that targeted and harmed economically disadvantaged minority children in the United
States and abroad as a result of these problems.
In Section V, I propose several ways to end targeting in the United States and
abroad. First, the justice principle must be redefined to mean equity in participation.
Equity in participation would require researchers to use non-disadvantaged children as
research subjects unless the study is a priority to and does not overburden
economically disadvantaged minority children. To measure whether equity in
participation is met, researchers should be required to use the proposed Vulnerability
and Equity Impact Assessment (VEIA) tool,11 to determine whether the selection of
children from particular groups as research subjects violates the redefined justice
principle. Finally, I suggest the creation of a Board of Children to review all medical
research studies regulated by the United States that use children as research subjects. If
all of these recommendations are implemented, it will prevent economically
disadvantaged minority children from being targeted in medical research studies for
the benefit of an unworthy society.
II. MEDICAL RESEARCH STUDIES INVOLVING CHILDREN: THE
STRUCTURE AND HISTORY
There are two types of medical research studies involving human subjects: Nontherapeutic and Therapeutic.12 Regardless of the type of medical research study, all
10
Leonard Glantz, Research with Children, 24 AM. J.L. & MED 213, 215-18 (1998); LEDERER &
GRODIN, supra note 4, at 12, 19. Children have also been exploited in medical research studies for
conditions that were not limited to children. Id. Moreover, many medical research studies conducted on
children produce minimal scientific benefits in comparison to their costs and are stigmatizing. See, e.g.,
Solomon R. Benatar, Global Health and Justice: Re-Examining Our Values, 27 BIOETHICS 297, 301-02
(2013); Iain Chalmers & Paul Glasziou, Avoidable Waste in the Production and Reporting of Research
Evidence, 374 LANCET 86 (2009); WASHINGTON, supra note 1, at 271-96; LAINIE ROSS, CHILDREN IN
MEDICAL RESEARCH: ACCESS VERSUS PROTECTION 48-56 (2006).
11
The Vulnerability and Equity Impact Assessment tool is based on the Health Equity Impact
Assessment tool. For a description and evaluation of the Health Equity Impact Assessment tool see
REBECCA HABER, HEALTH EQUITY IMPACT ASSESSMENT: A PRIMER (Wellesley Institute 2010) and Rainer
Fehr, Environmental Health Impact Assessment, Evaluation of a Ten-Step Model, 10 EPIDEMIOLOGY 618
(1999) (analyzing various ways to assess health impacts).
12
Declaration of Helsinki (1964), 313 BRIT. MED. J. 1448, 1448 (1996) (distinguishing between
research “in which the aim is essentially diagnostic or therapeutic for a patient” and that which “is purely
scientific and without implying direct diagnostic or therapeutic value to the person subjected”).
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studies using children entail risk of psychological and physical harm, as well as the
possibility of stigma. In fact, countless children have suffered harm as a result of study
participation, often without any benefit in return.13 Economically disadvantaged14
minority children have been and continue to be overrepresented in medical research
studies.15
A. STRUCTURE OF MEDICAL RESEARCH STUDIES INVOLVING HUMAN SUBJECTS
A non-therapeutic medical research study is conducted to obtain generalizable
scientific knowledge.16 This research is done to learn more “about the subjects'
disorder or condition which is of vital importance for the understanding or
amelioration of the subjects' disorder or condition.”17 An example of non-therapeutic
research is a study to ascertain the effects of household pesticide use on children’s
health.18
A therapeutic medical research study tests a vaccine, drug, or medical device for
the treatment of a disease.19 An example of a therapeutic medical research study is the
testing of HIV/AIDS drugs. There are five Phases of therapeutic medical research
studies: Phase 0, I, II, III, and IV.20 Using drug medical research studies as an
example, each Phase is discussed below.
In a Phase 0 drug study, research is conducted using at most ten people and
involves the administration of small doses of an experimental drug over a short period
of time to determine if there is any pharmacological effect.21 The purpose of the study
is to evaluate whether there is any effect in humans, before undertaking Phase I and II
drug studies.22 Unlike Phase I drug studies, there is no therapeutic intent and little to
no toxic effect in a Phase 0 drug study, which is primarily done for cancer drugs and
therapies.23

13

Glantz, supra note 10, at 215-18. See also Lederer & Grodin, supra note 4, at 12, 19.
Throughout the article, I use the term “economically disadvantaged” to discuss children who lack
access to essential goods such as food, housing, and health care. Although the term can be over inclusive, for
clarity, I have used the word accepted in the medical research community. For more discussion, see Carol
Levine, Changing Views of Justice after Belmont: AIDS and the Inclusion of “Vulnerable” Subjects, in THE
ETHICS OF RESEARCH INVOLVING HUMAN SUBJECTS: FACING THE 21ST CENTURY 105-24 (1996).
15
See, e.g., WASHINGTON, supra note 1, at 271-96, ROSS, supra note 10, at 48; Vernellia Randall,
Slavery, Segregation and Racism: Trusting the Health Care System Ain’t Always Easy! An African American
Perspective on Bioethics, 15 ST. LOUIS U. PUB. L. REV. 191, 199 (1996).
16
Declaration of Helsinki (1964), supra note 12. Children are allowed to participate in these studies
where they present more than minimal risk to the subjects only if “[t]he risk represents a minor increase over
minimal risk” and “[t]he intervention or procedure presents experiences to subjects that are reasonably
commensurate with those inherent in their actual or expected medical, dental, psychological, social, or
educational situations.” 45 C.F.R. § 46.406 (2015).
17
45 C.F.R. § 46.406.
18
For an example of one such study, see Jack K. Leiss & David A. Savitz, Home Pesticide Use and
Childhood Cancer: A Case-Control Study, 85 AM. J. PUB. HEALTH 249 (1995).
19
Declaration of Helsinki (1964), supra note 12.
20
NAT’L INSTS. OF HEALTH, Glossary of Common Site Terms, CLINICALTRIALS.GOV,
http://clinicaltrials.gov/ct2/info/glossary#Phasel (Feb. 2016) [https://perma.cc/V82C-BULR] (describing the
five phases under the definition of “Phase”).
21
Patient and Caregiver Resources: Phases of Clinical Trials, NAT’L COMPREHENSIVE CANCER
NETWORK (2016), https://www.nccn.org/patients/resources/clinical_trials/phases.aspx [https://perma.cc/
WE4Q-WRP5].
22
Id.
23
Phases of Clinical Trials, CANCER RESEARCH U.K., (Oct. 21, 2015), http://www.cancerresearch
uk.org/about-cancer/find-a-clinical-trial/what-clinical-trials-are/phases-of-clinical-trials
[https://perma.cc/
46RB-MAVZ].
14
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In a Phase I drug study, research is conducted using a small number of subjects,
less than 100 people, to obtain information regarding the safety and efficacy of the
candidate drug on human subjects.24 Phase II studies obtain information from several
hundred subjects regarding the subjects’ immune system’s response, the efficacy of the
drug on different populations, and the effect of different doses on the population.25
After preliminary evidence has been obtained suggesting effectiveness of the
drug, a Phase III drug study is conducted “to gather additional information to evaluate
the overall benefit-risk relationship of the drug and provide an adequate basis for
physician labeling.”26 Researchers determine the efficacy of the drug in preventing the
disease by following several thousand subjects.27 This is the last phase before the drug
is marketed and distributed.28 Phase IV is the final step in drug studies.29 It includes
“[p]ost-marketing . . . studies to delineate additional information about the drug's risks,
benefits, and optimal use.”30
The main difference between each Phase is the purpose of the study and the
benefit. In Phase 0, I, and II studies, the goal is primarily the attainment of scientific
knowledge, whereas in Phase III and IV studies, the goal is treatment.31 Many patients,
physicians, and scholars often misunderstand the difference between research and
therapy.32 Although there is no potential for a benefit in Phase 0, I, and II medical
research studies, many patients, providers, and even researchers believe that
enrollment in these studies is beneficial for the patient because the patient will receive
treatment.33 This therapeutic misconception is used to justify the targeting of
vulnerable research subjects, such as economically disadvantaged minority children,
for participation in medical research studies.34
B. EASILY MANIPULATED SUBJECTS: A BRIEF HISTORY OF TARGETING
Although the definitions seem clear, ascertaining whether a study is nontherapeutic or therapeutic can be difficult because both studies may potentially benefit
society through either generalizable knowledge or direct treatment. Nevertheless, no
matter whether the study is non-therapeutic or therapeutic, some researchers have
targeted economically disadvantaged minority children for use in medical research
studies, causing lifelong disability and/or death.35
24
Step 3: Clinical Research, U.S. FOOD & DRUG ADMIN., http://www.fda.gov/ForPatients/
Approvals/Drugs/ucm405622.htm (May 19, 2016) [https://perma.cc/N7PJ-VDAK].
25
Id.
26
NAT’L INSTS. OF HEALTH, supra note 20.
27
U.S. FOOD & DRUG ADMIN., supra note 24.
28
See id.
29
Id.
30
21 C.F.R. § 312.85 (2016). See also Leslie Pickering Francis, Legitimate Expectations,
Unreasonable Beliefs, and Legally Mandated Coverage of Experimental Therapy, 1 IND. HEALTH L. REV.
215, 228 (2004) (“Phase IV trials undertake continued collection of data after a new drug is given marketing
approval based on data from earlier trials. The goal of Phase IV is to collect data on an ongoing basis as an
approved therapy becomes employed in the general population of patients in need of treatment. Distribution
of a therapy into the general population of patients, outside the research context, may reveal quite different
aspects of the therapy's risks and benefits.”).
31
See Francis, supra note 30, at 228.
32
Oberman & Frader, supra note 6, at 308-10.
33
Francis, supra note 30, at 228-29.
34
Oberman & Frader, supra note 6, at 308-10.
35
WASHINGTON, supra note 1, at 271-96; Rupali Ghandhi, Research Involving Children: Regulations,
Review Boards and Reform, 8 J. HEALTH CARE L. & POL’Y 264, 264-65 (2005); Oberman & Frader, supra
note 6, at 308-10; Glantz supra note 10, at 215-17; Randall, supra note 15, at 199; Lederer & Grodin, supra
note 4, at 19.
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Between 1936 and 1960, psychiatrists and neurosurgeons conducted lobotomies
on healthy African American boys as young as five years old that obliterated their
thought ability and personality.36 The psychiatrists and neurosurgeons used crude tools
such as the icepickalon.37 Inserting the tools into the boys’ brains, the researchers
“blindly swept [the tools] back and forth . . . cutting all the connecting nerves,”
removing any chance for the once healthy boys to lead a normal life.38 From 1949 to
1960, the Medical College of Virginia conducted radiation tests on healthy African
American children, as young as six months old, deliberately causing third-degree burns
to their skin.39 In 1956, seventeen healthy African American infants were deprived of
an essential nutrient, which researchers knew the body could not survive without.40
Ten of the seventeen suffered severe complications, in order for scientists to determine
if canned milk caused skin rash, diarrhea, or slow weight gain.41 Notwithstanding the
complications, the study was repeated with 428 infants and seven of the infants died.42
The U.S. Atomic Energy Commission (AEC) “irradiated 235 African American
newborns from 1953 to 1954 in various hospitals across the nation” for no recorded
therapeutic purpose since the infants were healthy.43 Between 1960 and 1970, the AEC
sponsored a study in which radioactive material was added to the oatmeal of thirty
healthy orphans, some of which were African American.44 The government obtained
the bodies of the research participants who died to measure the levels of radioactivity
and biological damage.45
These are just a few examples of the targeting of economically disadvantaged
minority children in medical research studies for the benefit of society. The children
who participated in these studies were chosen because they were readily accessible and
in a compromised position, not because they were particularly affected by the
condition being studied. These historical abuses were the foundation for the
application of social justice to medical research studies and the protection of
vulnerable populations, particularly economically disadvantaged minority children,
from exploitation.46
III. THE JUSTICE PRINCIPLE: SOCIAL JUSTICE IN MEDICAL RESEARCH
STUDIES
The concept of social justice has been applied in the allocation of societal benefits
and burdens, such as “punishment, taxation and political representation.”47 Before
1979, most scholars, bioethicists, and researchers did not view social justice as

36

WASHINGTON, supra note 1, at 284.
Id.
38
Id.
39
Id. at 236-37. This is the example referenced in the Introduction of this article.
40
Id. at 294.
41
Globe Reports Research Team Deprived Infants of Essential Nutrient, LEWISTON EVENING JOURNAL
(Mar. 29, 1973), https://news.google.com/newspapers?id=oJggAAAAIBAJ&sjid=mmgFAAAAIBAJ&pg=
1205%2C3872215 [https://perma.cc/UQ6T-LNYB].
42
WASHINGTON, supra note 1, at 294
43
Id. at 238-39.
44
Id. at 233.
45
Id.
46
Randall Clark, Speed, Safety, and Dignity: Pediatric Pharmaceutical Development in an Age of
Optimism, 9 U. CHI. L. SCH. ROUNDTABLE 1, 44 (2002), reprinted in THE ETHICS AND REGULATIONS OF
RESEARCH WITH HUMAN SUBJECTS 529 (2005).
47
See Belmont Report, supra note 8, at 23,194.
37
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relevant to medical research studies.48 The first discussion concerning the proper
allocation of burdens and benefits of medical research studies appeared in the Belmont
Report’s discussion of the justice principle.49 This report, mandated by the United
States’ Congress, not only defined the term, but also provided the framework for
which to apply the principle to medical research studies.50 Since 1986, when the
Common Rule was enacted, the justice principle has been applied to all medical
research funded by the federal government.51 Beginning in 1996, the justice principle
was also applied to any medical research studies conducted outside the United States
by a company seeking drug approval in the United States.52
A. BELMONT REPORT
In the early 1970s, the U.S. Senate Committee on Labor and Human Resources
held hearings on some of America’s most egregious medical research studies, such as
the Willowbrook study53 and the Tuskegee Syphilis study.54 As a result of the
48
Lederer & Grodin, supra note 4, at 3, 18-19. The precursor to international protections of human
subjects participating in medical research studies was the Nuremberg Code in 1947, which was developed in
response to the Trials of War Criminals before the Nuremberg Military Tribunals. See Nuremberg Code
(1947), 313 BRIT. MED. J. 1448 (1996).
49
Belmont Report, supra note 8, at 23,194. In fact, the justice principle was found only in the Belmont
Report until 2000, when the World Medical Association added the principle to the Declaration of Helsinki, a
renowned document of bioethics for medical research. See Robert V. Carlson, Kenneth M. Boyd & David J.
Webb, The Revision and the Declaration of Helsinki: Past, Present, and Future, 57 BRITISH J. CLINICAL
PHARMACOLOGY 695, 699-704 (outlining the 2000 revisions to the Decaration of Helsinki). For a discussion
regarding the ethical documents that discuss the use of children in research trials, see Duane Alexander,
Regulation of Research with Children: The Evolution from Exclusion to Inclusion, 6 J. HEALTH CARE L. &
POL'Y 1, 1-3 (2002).
50
Belmont Report, supra note 8, at 23,196-97.
51
45 C.F.R. § 46.111(a)(3) (2015); Proposed Model Federal Policy for the Protection of Human
Subjects, 51 Fed. Reg. 20,204 (June 3, 1986) (providing the opportunity for the public comment that
provided the basis for the Common Rule); 53 Fed. Reg. 45,660 (Nov. 10, 1988) (recognizing that the
response to public comment on 51 Fed. Reg. 20,204 led to the development of the Common Rule).
52
INTERNATIONAL CONFERENCE ON HARMONISATION OF TECHNICAL REQUIREMENTS FOR
REGISTRATION OF PHARMACEUTICALS FOR HUMAN USE, GUIDELINE FOR GOOD CLINICAL PRACTICE 1
(1996) (providing “an international ethical and scientific quality standard for designing, conducting,
recording and reporting trials that involve the participation of human subjects”).
53
For fifteen years (1956-1971) researchers conducted a non-therapeutic medical research studies on
children at the Willowbrook State School, an institutional facility for mentally ill children on Staten Island,
New York. Carl Coleman, et al, Historical Antecedents: Medical Research in the United States from 1900 to
the Early 1970s, in THE ETHICS AND REGULATIONS OF RESEARCH WITH HUMAN SUBJECTS 39 (2005).
Researchers infected healthy children, thus the study was not to treat a disease from which the children
suffered. Early in the study the children were fed “extracts of stools from [Hepatitis-]infected children” and
injected with “more purified virus preparations” to determine “the natural history of hepatitis and the effects
of gamma globulin in preventing or moderating its effects.” Id. While the study led researchers to develop a
hepatitis vaccine and better understand the differences between Hepatitis A and B, healthy children were
infected with life-long debilitating diseases. Id. The infected children could never use the new vaccine, and
as a result of the studies were subject to costly treatment for the rest of their lives.
The researchers defended their work by noting hepatitis “was prevalent in the institution.” Id. They
assumed the children would eventually acquire the disease. Id. Major medical journals (the Journal of the
American Medical Association and the New England Journal of Medicine) published the results of the study,
commending the researchers for their use of vulnerable children. Id. (noting that Franz Inglefinger argued in
the New England Journal of Medicine that “the children benefited from being infected under carefully
controlled research conditions and receiving expert attention.”) Furthermore, many scholars argue that
parental consent forms were not entirely voluntary as due to overcrowding, the only way to have a child
admitted to Willowbrook was through the hepatitis study. Id.
54
See Belmont Report, supra note 8, at 23,194. The Tuskegee Syphilis Study, conducted from 1932
through 1972, denied economically disadvantaged African-American men access to standard treatment. See
generally JAMES H. JONES, BAD BLOOD: THE TUSKEGEE SYPHILIS EXPERIMENT (1981).
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hearings, Congress created the National Commission for the Protection of Human
Subjects of Biomedical and Behavioral Research (Commission).55 In addition,
Congress imposed a moratorium on research conducted or supported by the U.S.
Department of Health and Human Services (HHS) on a living human fetus56 until
adequate protections for such subjects were developed.57
The Belmont Report was an outgrowth of the Commission’s deliberations
regarding ethical protections and a 1976 conference at the Smithsonian Institute’s
Belmont Conference Center.58 In the Belmont Report, the Commission selected justice
as one of the three fundamental ethical principles to protect vulnerable groups from
exploitation in medical research studies.59 The Commission noted that in the United
States the burden of participating in medical research studies was borne principally by
the economically disadvantaged while the rich enjoyed the benefits, as evidenced by
the Tuskegee Syphilis Study.60
From 1932 until 1972, researchers enrolled economically disadvantaged black
men in a study to document the course of syphilis, even though the course of the
disease was already known.61 In exchange for free meals, medical exams and burial
insurance, the researchers promised the men that they would provide treatment for
their ‘bad blood,” which could include “anemic blood to muscle aches, general
malaise, disorders such as parasitic infections, gonorrhea, syphilis, and other venereal
disease.”62 The researchers never informed the men that they were participating in a
medical research study, and therefore, never told them about the purpose of the
study.63 Researchers also intentionally deprived these men of “demonstrably effective
treatment in order not to interrupt the project, long after such treatment became
generally available,” causing the unnecessary disability and death of the men, their
wives, and their children.64 The study was not a therapeutic study because it was not

55
Belmont Report, supra note 8, at 23,192. The Commission was composed of eleven members
appointed by the Secretary of HHS. Protection of Human Subjects of Biomedical and Behavioral Research
Act, Pub. L. No. 93-348, § 201, 88 Stat. 348 (1974). The National Research Act advised the Secretary of
HHS to choose the members of the Commission from distinguished individuals from the fields of medicine,
law, ethics, theology, philosophy, humanities, health administration, government, public affairs, and the
biological, physical, behavioral, and social sciences. Id. Five of the members of the Commission had to be
individuals engaged in biomedical or behavioral research involving human subjects. Id. Members of the
Commission included Dorothy I. Height, President of the National Council of Negro Women, Inc., Dr.
Albert R. Jonsen, Associate Professor of Bioethics at the University of California at San Francisco, and
Patricia King, Associate Professor of Law at Georgetown University Law Center. Office for Human
Research Protections, The Belmont Report, HHS.GOV (March 15, 2016), http://www.hhs.gov/ohrp
/regulations-and-policy/belmont-report/ [https://perma.cc/6665-WG3C].
56
Prior to 1980 and the enactment of the National Research Act, the U.S. Department of Health and
Human Services was originally named the U.S. Department of Health, Education, and Welfare. See
Department of Education Organization Act, Pub. L. No. 96-88, § 509(e), 93 Stat. 695 (1979) (codified at 20
U.S.C. § 3508 (2012). To avoid confusion when discussing events before and after the name change, I refer
to the agency only as the U.S. Department of Health and Human Services.
57
Pub. L. No. 93-348, § 213, 88 Stat. at 353.
58
Belmont Report, supra note 8, at 23,192.
59
Id. at 23,194. The two other principles were respect for persons and beneficence. These principles
focus on ensuring that the subjects’ choices are voluntary (respect for persons) and that subjects are not
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testing a possible treatment of syphilis and blocked any access to treatment.65
Additionally, the study was not a non-therapeutic study to attain generalizable
knowledge because the medical community had already documented the disease
process of syphilis.66 Thus, there was nothing gained from the study other than
exploiting the economically disadvantaged and minorities.
To put an end to the exploitation of the economically disadvantaged and
minorities, the Commission incorporated social justice into the ethical principles
governing medical research studies using human subjects.67 Specifically, the
Commission created the justice principle to determine “Who ought to receive the
benefits of research and bear its burdens?”68 To answer this question and establish the
contours of the justice principle, the Commission defined what is just and what is
unjust in the selection of research subjects.69
In selecting research subjects, the justice principle requires that researchers ensure
disadvantaged groups such as minorities, women, children, the institutionalized
mentally infirm, prisoners, and the economically disadvantaged70 are not “being
systematically selected simply because of their easy availability, their compromised
position, or manipulability, rather than for reasons directly related to the problem
being studied.”71 The Commission reasoned that:
whenever research supported by public funds leads to the development of therapeutic
devices and procedures, justice demands both that these not provide advantages only to
those who can afford them and that such research should not unduly involve persons from
groups unlikely to be among the beneficiaries of subsequent applications of the research.72

According to the Commission, “the principle of justice gives rise to moral
requirements that there be fair procedures and outcomes in the selection of research
subjects” on two levels: Individual and Social.73 On the Individual level, researchers
should include the disadvantaged in potentially beneficial research that is usually
reserved for the rich, instead of using them for non-therapeutic and dangerous medical
research studies.74 On the Social level, researchers must draw a distinction “between
classes of subjects that ought, and ought not, to participate in any particular kind of
research, based on the ability of members of that class to bear burdens and on the
appropriateness of placing further burdens on [an already burdened group].”75 The
Belmont Report noted that it was not fair for the economically disadvantaged, who rely
on public funds for health care, to be considered as preferred research subjects for
publicly funded research because of their need to access health care.76 Thus, there is an
order of preference in the selection of research subjects, such that researchers should
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use the rich before the economically disadvantaged, the majority before minorities, and
adults before children.
On an Individual level, the justice principle requires inclusion of vulnerable
groups for potentially beneficial research, while on a Social level this inclusion must
be limited to protect vulnerable groups from being overburdened.77 Nevertheless, even
after researchers balance the Individual and Social level requirements of the justice
principle, the use of certain classes of people for research may be unjust because of
“social, racial, sexual, and cultural biases institutionalized in society” that place a class
of people in a vulnerable and compromised position, easily manipulated into
participating in medical research studies.78
For example, over three decades of empirical research studies show that racial
bias institutionalized in society prevents many African Americans from receiving
quality education, obtaining jobs, and accessing housing in safe, diverse, and
environmentally-friendly neighborhoods.79 Studies show that African Americans
seeking employment have a harder time obtaining employment because non-African
American managers tend to hire more Caucasians.80 Also, African Americans with
non-Caucasian names receive fifty percent less callbacks than African Americans with
Caucasian sounding names.81 As a result, many African Americans are more likely to
be unemployed or employed with no health insurance.82 Lacking health insurance or
money to pay for health care, African Americans are left in a compromised position
77

See id. at 23,196.
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and easily manipulated into participating in medical research studies to obtain access
to health care. Consequently, even if researchers fairly select African Americans as
research subjects, without bad intent, these institutional racial biases, which place
African Americans in a vulnerable and compromised position, easily manipulated into
participating in medical research studies, make their use as research subjects a
violation of the justice principle.83 To counteract these unjust social patterns the
Belmont Report requires researchers to consider distributive justice in selecting
research subjects and follow the order of preference, using the rich before the
economically disadvantaged, the majority before minorities, and adults before
children.84
B. FEDERAL REGULATION
PRINCIPLE

OF

MEDICAL RESEARCH STUDIES

AND THE

JUSTICE

In 1986, the Belmont Report in its entirety, was adopted by sixteen federal
agencies and departments, including HHS, and codified in 45 C.F.R Part 46 (the
Common Rule).85 In fact, not only did the Common Rule make the justice principle
law, but also it explicitly defined the groups protected by the justice principle as
vulnerable populations that shall not be targeted.86 Vulnerable populations include
minorities, children, prisoners, pregnant women, mentally disabled persons, and
economically or educationally disadvantaged persons.87 It governs all research studies
conducted by or funded by the federal government, except for those studies conducted
in emergency settings.88
Institutions receiving federal funding to conduct medical research must enter into
a contractual agreement with the federal government, called an assurance, asserting
that they will comply with the Common Rule.89 Once an institution’s assurance is
approved and it receives federal funding, the federal government requires that all
research conducted by the institution regardless of who funds it comply with 45 C.F.R
Part 46. The Office for Human Research Protections (OHRP), a federal agency housed
within HHS, is responsible for ensuring that institutions comply with their assurances
and the Common Rule.90 To fulfill this task, OHRP may request additional information
in writing, conduct telephone interviews, or conduct site visits.91 These visits can be
random or in response to allegations of noncompliance with the Common Rule.92
83
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When reviewing allegations of noncompliance, OHRP grants the institution an
opportunity to refute the allegations.93 Once additional information is obtained, OHRP
determines whether the institution has violated the law.94 OHRP issues corrective
action for instances of noncompliance, which is in “the best interest of human research
subjects, and to the extent possible, the institution, the research community, and
HHS.”95 Corrective action may include restriction or withdrawal of approval for an
institution’s assurance and suspension or permanent removal from participation in
specific projects.96 Information regarding allegations and findings of noncompliance
can be found on OHRP’s website.97
OHRP is responsible for reviewing compliance at the institutional level.98 Every
institution that has an assurance with OHRP is responsible for ensuring that individual
medical research studies conducted by those affiliated with the institution comply with
the Common Rule.99 To accomplish this task, all institutions and federal agencies that
enter into an assurance with OHRP have an Institutional Review Board (IRB).100 There
are an estimated 3,000 to 5,000 IRBs, which serve as the main protection for
vulnerable populations in medical research studies.101
Before researchers can conduct medical research studies using human subjects in
the United States or be funded by the United States government to conduct medical
research studies using human subjects, they must submit a research protocol to their
IRB.102 A complete research protocol includes a statement of compliance with the
ethical principles, such as the justice principle.103 The IRB reviews all written research
protocols in application for medical research studies using human subjects to ensure
that the proposed studies comply with the Common Rule, including the ethical
requirements of the justice principle.104 If the IRB finds that the research protocol is
ethical, they can approve the research to be conducted and/or submitted for funding to
the United States government.105 The IRB can also require modifications in the
research protocol or disapprove any research protocol.106
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In terms of the justice principle, the IRB is required to ensure that the “risks to
subjects are minimized . . . by using procedures which are consistent with sound
research design and which do not unnecessarily expose subjects to risk”107 and the
selection of subjects is “equitable.”108 In order to determine if the selection of subjects
is equitable the IRB is required to ensure that vulnerable populations are not targeted
by taking into account the purposes of the research, the setting in which the research
will be conducted, and the need to protect vulnerable populations.109 If the IRB allows
vulnerable populations to be targeted, the institution is in violation of their assurance
and subject to corrective action by OHRP. Not only does the justice principle apply to
research conducted in the United States or funded by the United States government,
but it also governs research used to seek drug approval in the United States.110
C. ICH-GP
The International Council for Harmonisation of Technical Requirements for
Registration of Pharmaceuticals for Human Use (ICH) “is a unique project . . . [that]
brings together the regulatory authorities of Europe, Japan and the United States and
experts from the pharmaceutical industry in the three regions to discuss scientific and
technical aspects of product registration.”111 The sole purpose of ICH is “to make
recommendations on ways to achieve greater harmonisation in the interpretation and
application of technical guidelines and requirements for product registration in order to
reduce or obviate the need to duplicate the testing carried out during the research and
development of new medicines.”112 The ICH developed the Good Clinical Practice
guidelines (GCP), “an international ethical and scientific quality standard for
designing, conducting, recording and reporting [medical research] trials that involve
the participation of human subjects.”113 Researchers generating medical research study
data to be submitted to regulatory authorities in the EU, Japan, and the United States,
must comply with the ICH-GCP in order to have their drug approved in these
countries.
Overall, “the objective of this ICH-GCP … is to provide a unified standard for the
EU, Japan, and the United States to facilitate the mutual acceptance of clinical data by
the regulatory authorities in these jurisdictions,” while protecting medical research
subjects.114 Developed using ethical principles around the world to protect among
other things, vulnerable populations from being targeted in medical research studies,
the ICH-GCP defines vulnerable subjects as those who are economically
disadvantaged, minority groups, and/or minors.115 To protect these vulnerable
populations the ICH-GCP states that IRBs have to pay special attention to medical
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research studies that include subjects from vulnerable populations.116 Additionally, the
ICH-GCP incorporates all of the principles of the Declaration of Helsinki.117
The Declaration of Helsinki, drafted and adopted in 1964 by the World Medical
Association, is a statement of ethical standards that was designed as a guide to
physicians and others participating in medical research studies involving human
subjects, in addition to the responsibilities imposed by their own countries.118 In 2000,
thirty-six years after the adoption of the document,119 the World Medical Association
amended the Declaration of Helsinki to include the justice principle. 120
Similar to the justice principle espoused in the Belmont Report, the Declaration of
Helsinki advises medical researchers that vulnerable populations should not be
targeted for medical research studies.121 Specifically, the Declaration of Helsinki states
“[M]edical research with a vulnerable group is only justified if the research is
responsive to the health needs or priorities of this group and the research cannot be
carried out in a non-vulnerable group.”122 Hence, medical researchers cannot use
human subjects from vulnerable populations just because they are readily available,
easily manipulated into participating, or in a compromised position. Instead there is an
order of preference in the selection of research subjects to use those from nonvulnerable groups first.123 The incorporation of the justice principle into the ICH-GCP
demonstrates clearly the importance of the principle in protecting research subjects
across the world.
Unfortunately, since the implementation of the justice principle in U.S. and
international law, members of vulnerable populations continue to be targeted for
medical research studies because of structural problems in the regulation process and a
paradigm shift in the meaning of the justice principle. The regulatory problems,
reasons for this shift, and examples of the egregious harm caused by both are discussed
below.
IV. PRIVATE REGULATION AND INCLUSION: BARRIERS TO
ENFORCEMENT OF THE JUSTICE PRINCIPLE
Structural flaws in the regulation of medical research studies have allowed
researchers to often ignore the justice principle’s prohibition against targeting.
Moreover, in 1990, only four years after being applied to medical research studies,
there was a “paradigm shift” in the use of the justice principle that has allowed
researchers to target economically disadvantaged minority children in the name of
116
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inclusion.124 Specifically, instead of using the justice principle to protect economically
disadvantaged minority children from researcher’s targeting, now researchers use the
justice principle to grant economically disadvantaged minority children a ‘fair
opportunity’ to participate in medical research studies.125 Proponents of inclusion have
three main arguments.
First, they argue that inclusion provides economically disadvantaged minority
children with access to innovative drugs.126 This argument misapprehends the true
meaning and nature of medical research. Medical research is not treatment and can be
a dangerous endeavor that causes significant harm and death.127 Second, they argue
that the justice principle kept vulnerable populations, such as economically
disadvantaged minority children, from participating in medical research studies.128
Empirical research shows that economically disadvantaged minority children never
stopped participating in medical research studies.129 Third, proponents of inclusion
argue that children are therapeutic orphans, meaning that they do not have drugs to
address their specific health care needs, because the justice principle limits children’s
participation in medical research studies.130 However, children have been therapeutic
orphans since 1963, sixteen years before the creation of the justice principle.131 As a
result of these regulatory and interpretation problems, economically disadvantaged
minority children are still targeted for medical research studies.
A. ENFORCEMENT FAILURES IN THE REGULATION OF MEDICAL RESEARCH STUDIES
The current regulatory system is ineffective at protecting children from being
targeted because the regulation of the justice principle has been left to the discretion of
the very institutions that target vulnerable populations.132 The government delegated
the authority to prevent targeting to IRBs, which are housed within the institutions that
employ the researchers seeking grants.133 Because this money benefits the institution
as well as the researcher, IRBs are often reluctant to deny approval of research
protocols.134
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In fact, scholars have noted that IRBs often fail to comply with federal law
because they are “too weak, overburdened, ignorant, or conflicted.”135 The failure of
IRBs to comply with the law is particularly troubling in instances concerning the
justice principle because the IRB is the main protector of the vulnerable against
targeting by researchers. Data also suggests that IRBs rarely review protocols for
compliance with the justice principle compared to other requirements such as
autonomy (informed consent).136
Empirical evidence shows that IRBs returned “only 10 percent of research
proposals . . . to investigators for clarification of subject selection,” while IRBs
returned “the consent portion of proposal . . . for correction 25 percent of the time.”137
Moreover, if the proposed research subject is a pediatric patient in a hospital or clinic
and a consenting parent or guardian is present, the researcher’s motives for including
the child are never investigated.138 Additionally, the burdens borne by these children
because of their socioeconomic and minority status are rarely measured.139 Thus, it is
not surprising that some researchers continue to target economically disadvantaged
minority children for use in medical research studies.
Another reason for the persistent targeting of vulnerable populations is lax federal
oversight. Scholars note that OHRP barely reviews IRB compliance with the Common
Rule.140 Furthermore, there is no mandatory public reporting of medical research
studies conducted in the United States or in foreign countries.141 Consequently, IRB
decisions regarding the selection of research subjects are never disclosed to the public
unless there are allegations made to OHRP or to the media that the Common Rule has
been violated. Even if IRBs and the OHRP enforced the Common Rule, there would
still be issues with research subject selection because the regulations and government
guidance are devoid of meaningful practical advice on how to ensure that subjects are
selected equitably according to the justice principle.142
The OHRP issued an IRB Guidebook, a non-binding guidance to assist IRBs in
fulfilling their responsibilities in protecting the rights and welfare of human
subjects.143 Chapter VI of the Guidebook addresses special classes of subjects, which
includes all of the groups listed in the vulnerable population definition in the Common
Rule.144 Even though the Guidebook was issued in 1993, it is telling that the only
discussion regarding the selection of subjects is in response to cognitively impaired
persons.145 There is no discussion about the equitable selection of children or
minorities, the main groups whose targeting served as the basis for the creation of the
justice principle.146 Furthermore, even though the Guidebook addresses the use of
children and foster children in medical research studies, these guidelines only focus on
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autonomy (informed consent) and beneficence (the best interest of the child based on a
benefit risk analysis), not the justice principle.147
The lack of guidance in applying the justice principle is highlighted in the medical
research literature. As T. Howard Stone notes, “[T]here is a dearth of literature
addressing how IRBs should approach the review of research involving persons who
are economically or educationally disadvantaged.”148 Consequently, persons from
vulnerable populations “remain unduly vulnerable to clinical research risks, and they
have become the ‘invisible vulnerable.’”149 These regulatory failures are compounded
by the shift in interpretation of the justice principle from protection to inclusion.

B. PROTECTION TO INCLUSION: THE PROBLEM OF INTERPRETATION
The justice principle was only in effect for four years, when the federal
government shifted its view from protection of vulnerable populations, to inclusion of
vulnerable populations to promote greater access to medical research studies.150 This
campaign to change the meaning of the justice principle was a result of three things: 1)
HIV/AIDS epidemic; 2) the perceived lack of participation of economically
disadvantaged minority children in medical research studies; and 3) the therapeutic
orphan problem. In response to these three events, civil rights organizations, patients,
physicians, and researchers began advocating for the right of vulnerable populations,
particularly economically disadvantaged minority children, to participate in medical
research studies to gain access to potentially life-saving treatment. Unfortunately,
inclusion has not provided the benefits that advocates were fighting for. Instead, it has
provided the justification for targeting economically disadvantaged minority children
for participation in medical research studies.
1. Therapeutic Misconception
In the 1990s, medical research became synonymous with treatment. Carol Levine
notes that the HIV/AIDS epidemic is responsible for the paradigm shift.151 As a result
of the HIV/AIDS crisis, people were dying with no hope for treatment. New
HIV/AIDS drugs and therapies were being tested in medical research studies, but not
available to the general public. Consequently, HIV/AIDS medical research was viewed
as “cutting-edge medical treatment” not “experimental research” that could cause
serious harm.152 Thus, some HIV/AIDS activists began to argue that medical research
“served as an important means of access to otherwise unobtainable and theoretically
helpful new therapies.”153 In fact, some HIV/AIDS activists began to argue that access
to medical research studies for vulnerable populations should be considered an
essential good, like food and housing, rather than a risk from which vulnerable
populations should be protected.154 However, these arguments misinterpret the true
nature of medical research.
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Medical research studies are not therapeutic and do not guarantee life-saving
medicine. This is a therapeutic misconception.155 Although there is no potential for a
benefit in Phase I and II medical research studies, many patients, providers, and even
researchers believe that enrollment in these studies is beneficial for the patient because
the patient will receive treatment.156 This therapeutic misconception is often used to
justify the targeting of vulnerable populations to serve as research subjects, such as
economically disadvantaged minority children, in medical research studies.157
Participation in medical research studies is also not an essential good, like food,
which economically disadvantaged minority children are often denied.158 Unlike an
essential good, there are risks associated with participation in medical research studies
including stigma, long-term disability, and death. For example, in the late 1980s,
researchers in Los Angeles gave healthy African American infants five hundred times
the approved dose of an experimental measles vaccine, which had already sickened
and killed children in Senegal, Mexico, and Guinea-Bissau.159 Not only did this
medical research study not provide any treatment, but it also caused harm.
In the 1990s, the Kennedy Krieger Institute researchers investigating cheaper lead
abatement techniques partnered with landlords to partially abate lead tainted housing
in Baltimore.160 In order to test the efficacy of the abatement procedures, the
researchers in collaboration with the landlords ensured that only families with healthy
children lived in the lead tainted housing by agreeing to pay for abatement procedures
if the landlords rented to families with young children.161 Due to the racial makeup of
the neighborhood, the young children participating in the study were all minorities.162
Even though the information given to parents “implied that the study was
protecting their children from lead damage and promised to inform parents of any
hazards,” such as abnormal tests showing high lead levels, the study was nontherapeutic because it provided no benefit to the participants.163 In fact, the researchers
did not notify the parents of their children’s elevated lead levels or lead hot spots in the
house.164 As a result, many of the healthy children suffered exposure to lead, which
can cause inattention, irritability, hyperactivity, learning and reading delays, delayed
growth and hearing loss, permanent brain damage, and even death.165 Thus, this study
did not provide treatment or a benefit to society, and it caused harm.
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From 1992 to 1997, researchers at Columbia University’s Lowenstein Center for
the Study and Prevention of Childhood Disruptive Behaviors and New York City’s
New York State Psychiatric Institute conducted research to try to show a link between
genetics and violence, using only healthy and non-violent African American and
Latino children.166 The researchers administered fenfluramine to 126 boys between the
ages of six and ten, even though the drug had already been shown to cause heart-valve
damage, pulmonary hypertension (a life-threatening form of high blood pressure),
brain damage, and death in adults.167
As a result of participating in the study, children suffered physical harm including
but not limited to anxiety, fatigue, headaches, lightheadedness, difficulty
concentrating, visual impairment, diarrhea, and nausea.168 No generalizable knowledge
was obtained from this study because the premise of the research was that genetics was
linked with violence had been disproven by over a century of research.169 Furthermore,
the researchers’ use of only minorities in the study, even though Caucasians also
commit acts of violence, sent the message that minorities are more violent than
Caucasians and thus must be studied.170 Thus, inclusion of minority children in the
study did not grant them access to new medicine or treatment and it caused harm.
These studies are not outliers. In fact, empirical data shows that in comparison
with their percentage in the U.S. census, African American children continue to be
overrepresented in non-therapeutic medical research studies and underrepresented in
Phase III therapeutic medical research studies.171 This means that when compared to
Caucasians, African American children participate in medical research studies that
may not add to scientific knowledge beneficial to society, but not in medical research
studies that will be beneficial for them as a group by providing treatment.
Hence, the justice principle must mean more than a ‘fair opportunity’ for
economically disadvantaged minority children to participate in medical research
studies that are meaningless or can cause long-term disability or death. This holds true
especially for economically disadvantaged minority children, who have already been
denied the essential goods of food, housing, education, and access to health care.
2. The Myth of Protection: Participation in Medical Research Studies Never Stopped
In the 1990s HIV/AIDS disproportionately affected vulnerable populations
allegedly protected from the harms of medical research (women, minorities, and
children); these vulnerable populations, civil rights organizations, physicians, and
researchers advocated for the populations’ right to participate in medical research
studies to gain access to potentially life-saving treatment. The argument for the need
for inclusion was further bolstered by media reports that minorities and children lacked
access to HIV/AIDS drug studies.
For example, using National Institutes of Health (NIH) documents, a reporter
noted in a front page Los Angeles Times article that African Americans, Latinos, and
groups disproportionately afflicted with HIV/AIDS were significantly
underrepresented in federally-sponsored HIV/AIDS clinical trials.172 Advocates of
inclusion also argued that children with HIV/AIDS in the United States did not receive
166
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AZT until three years after adults gained access to AZT because children were denied
participation in medical research studies as a result of the justice principle.173
The theory of inclusion is based on an incorrect assumption that economically
disadvantaged minority children were not participating in medical research studies,
including those related to HIV/AIDS.174 However, even once the justice principle was
adopted, economically disadvantaged minority children were being targeted for, and as
a result, participating in medical research studies.
For example as discussed in more detail in subsection C, economically
disadvantaged healthy African American and Latino children in the United States and
abroad were used as research subjects in Phase I and II HIV/AIDS drug studies.175
Research shows that not only did some of these healthy children experience long-term
disability or die as a result of their participation in these studies,176 but it also shows
that many economically disadvantaged minority children in the United States and
abroad still do not have access to this medicine.177
Continuing lack of access to HIV/AIDS drugs is illustrated by a medical research
study conducted by a U.S. researcher. Funded by the U.S. government, the research
study used economically disadvantaged HIV-positive children in the Dominican
Republic “to determine if massage therapy would boost the immune systems” of the
children.178 “The children were ‘randomized’ into two groups. One received
therapeutic massage; the other, made up of twelve HIV-positive children, met with a
nurse for ‘reading, talking, playing quiet games’ as part of the friendly visit control
group.”179 The results from the study were reported in The Journal of Alternative and
Complementary Medicine.180 In this study, the inclusion doctrine was used to give
economically disadvantaged minority children a ‘fair opportunity’ to participate in
medical research studies that did not provide them with any access to HIV/AIDS
drugs.181 The research did not address the problem of children as therapeutic
orphans.182 Instead, it continued the practice of targeting minority children already
living in poverty for medical research studies.183
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3. Therapeutic Orphans
In the 1990s, the federal government, health care providers, and parents were
worried about the fact that children were ‘therapeutic orphans’ because “more that 75
percent of drugs marketed [to children] in the United States” had never been tested in
children.184 Arguing for the inclusion of children in medical research studies, “patient
advocates and some clinicians have noted that, in the interest of good medical care,
drugs should be tested on the populations that will use them.”185 Although this lack of
testing is definitely a problem, the failure to test drugs on children was not a result of
the four years of protection from targeting granted by the justice principle.
Children have been ‘therapeutic orphans’ since 1963,186 at a time when
researchers were putting radioactive material in healthy children’s oatmeal, cutting out
parts of the brain of healthy children, injecting healthy children with Hepatitis, and
using radiation to cause third-degree burns on healthy children as young as six months
old.187 Hence, the therapeutic orphan problem was not a result of the protections
required by the justice principle. It is not surprising that the shift to inclusion did not
increase medical research studies using children. In fact even after the shift to
inclusion, the U.S. government had to encourage pharmaceutical companies to conduct
medical research studies on children.188
In 1997, Congress passed the Food and Drug Administration Modernization Act
(FDAMA) to incentivize pharmaceutical companies to conduct medical research on
children by providing an additional six months of patent exclusivity to the companies
even if the results were negative or inconclusive.189 The government hoped that the
medical research would provide safety and efficacy information for drugs and
therapies used on children, ensuring that they were no longer therapeutic orphans.190 In
2000, Congress passed the Children’s Health Act, which included the Pediatric
Research Initiative.191 The law made medical research studies of childhood illness and
conditions a priority, however, funding for research using children still lagged behind
funding for all other medical research.192 In 2002, Congress extended the FDAMA
incentives in the Best Pharmaceuticals for Children Act (BPCA), which provided
government subsidies for medical research studies testing drugs no longer under
patent.193 A year later, Congress passed the Pediatric Research Equity Act, which
requires that all new pharmaceuticals be tested on children.194
Federal agencies and groups have also tried to increase the use of children in
medical research studies. In 1998, the NIH issued policy guidelines requiring all NIHfunded research to “include a plan for the inclusion of children, unless there is good
justification to exclude them.”195 The Institute of Medicine (IOM) also issued a report
about the use of children in medical research studies in response to a mandate in the
184
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BPCA. The purpose of the IOM report was to increase the participation of children in
medical research studies.196 Consequently, the IOM recommendations focused on
access instead of protection including paying children to participate in medical
research studies and permitting waivers of consent.197
As a result of these efforts, between 1987 and 2006, 135 drugs were granted
extended patent exclusivity and approximately 150 new drugs were approved through
studies using children.198 Notwithstanding these incentives, children still remain
therapeutic orphans. Pharmaceutical companies have focused on conducting medical
research studies on children for drugs with a large adult market.199 Sometimes these
studies have resulted in death or long-term disability. For example, in 2013, the U.S.
Food and Drug Administration (FDA) halted all pediatric medical research studies of a
calcium-lowering drug used in adults because of the death of a fourteen year old
participating in the study.200 The drug was not geared to treat a childhood specific
illness.201 Thus, inclusion of children in medical research studies has not fixed the
therapeutic orphan problem.
C. RESULTING HARM: TARGETING FOR INCLUSION
Even when included in medical research studies conducted to find pediatric drug
uses, many children are still targeted for medical research studies, resulting in serious
harm. Below is a brief summary of the most notable studies.
1. Studies in the United States
For thirteen years (1988-2001), Illinois, Louisiana, Maryland, New York, North
Carolina, Colorado, and Texas enrolled foster children, between the age of three
months to nineteen years old, in Phase I and II drug studies for the treatment of the
HIV/AIDS.202 Many of the foster children used for the study were African American
or Latino and were economically disadvantaged.203 The studies were conducted to
determine the drug toxicity and adverse side effects of drugs that had not been shown
196
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to be safe in adults.204 Funded in part by the NIH, the trials exposed the drug toxicity
and adverse side effects of potential HIV/AIDS drugs not yet proven to be safe for
children.205 There were a plethora of problems with the studies, including the targeting
of economically disadvantaged minority foster children because of their manipulability
and compromised position.206
In response to innumerable complaints and newspaper exposés, OHRP finally
investigated the use of economically disadvantaged minority children in HIV/AIDS
drug studies and found that their use was inequitable. Seventeen years after the
HIV/AIDS drugs studies started, OHRP issued a letter to the head of the IRB at
Columbia University Medical Center, noting that some of the HIV/AIDS drug studies
conducted at their institution violated the law.207 Specifically, the IRB approved
research protocols in which researchers had inequitably targeted economically
disadvantaged minority children in foster care to participate in the studies.208 In 2006,
OHRP sent letters of violation to fourteen other universities conducting HIV/AIDS
drug studies.209 Each letter noted that the universities had targeted economically
disadvantaged minority foster children in violation of the justice principle and the
Common Rule.210
Nevertheless, OHRP did not put an end to the studies, did not impose any
sanctions, and its findings failed to directly address the actions of the researchers who
violated the justice principle.211 Consequently, the researchers who conducted the
studies were able to publish their findings in medical journals without repercussions.
In issuing its findings, OHRP did not even explain why they found that the studies
targeted economically disadvantaged minority children as research subjects, but I
suggest several reasons.
204

Id.
Solomon, supra note 175.
206
In addition to this subjection of economically disadvantaged minority children to hazardous drug
trials, some researchers failed to obtain proper consent from participate in the trials. There were two
common practices that violated the informed consent laws. First, five children participating in the New York
drug trials between five and ten years of age were asked to sign consent forms once they were told of the
risks and benefits. See Solomon, supra note 175. Second, many of the researchers failed to obtain consent
from an authorized person, such as an independent advocate, for each child. Id. The only consent researchers
obtained for participating foster children were blanket consents from child welfare agencies. Id. None of the
200 Illinois foster children were appointed independent monitors even though researchers signed a document
guaranteeing “the appointment of an advocate for each individual ward participating in the respective
medical research.” Id. In New York, monitors were only appointed to less than one-third of the 465 foster
children participating in the medical research studies. Id.
207
See Letter from Karena Cooper, supra note 202.
208
Id. at 2.
209
The following institutions received letters determining that they had selected foster children
inequitably: Bellevue Hospital Center, Bronx-Lebanon Hospital Center, Children’s Hospital of King’s
Daughters, Children’s Hospital Association, Children’s Hospital of Philadelphia, Children’s Hospital and
Research Center at Oakland, Children’s Hospital and Regional Medical Center, Cook County Bureau of
Health Services, Drexel University College of Medicine, Duke University School of Medicine, Johns
Hopkins University/Johns Hopkins Health System, State University of New York-Upstate Medical
University, University of Chicago, and University of Miami. See, e.g., Letter from Kristina C. Borror, Dir.,
Div. of Compliance Oversight, Dept. of Health & Human Servs., to Lynda D. Curtis, Senior Vice President
& Exec. Dir., Bellevue Hosp. Ctr. (June 19, 2006), http://www.hhs.gov/ohrp/compliance-andreporting/determination-letters/index.html; Letter from Julia Gorey, Div. of Compliance Oversight, Dept. of
Health & Human Servs., to Steve Anderman, Senior Vice President & Chief Operating Officer, BronxLebanon Hosp. Ctr. (June 19, 2006), http://www.hhs.gov/ohrp/compliance-and-reporting/determinationletters/index.html. Additional letters available at http://www.hhhs.gov/ohrp/compliance-and-reporting/
determination-letters/index.html.
210
See OHRP letters, note 209.
211
Id.
205

AMERICAN JOURNAL OF LAW & MEDICINE

820

First, the selection of the children for participation in the HIV/AIDS drug studies
violated the justice principle’s order of preference for selecting subjects. The
preference requires that adults are used before children, the rich before the
economically disadvantaged, and the majority before the minority.212 Some of the
drugs tested in children were simultaneously being tested in adults.213 Second, the
children were public wards and according to the justice principle, researchers are not
allowed to use the economically disadvantaged, who rely on public funds for health
care, to be used as research subjects for publicly funded research.214
Third, not all the children used in the HIV/AIDS drug studies were even tested for
HIV/AIDS.215 The states gave blanket consent for the use of these children instead of
reviewing the files of each child to see if the child was even infected with
HIV/AIDS.216 Thus, it can be argued that the children were selected simply “because
of their easy availability, their compromised position, or manipulability, rather than for
reasons directly related to the problem being studied.”217
Fourth, the healthy children were unnecessarily “exposed . . . to risks of medical
research and drugs that were known to have serious side effects in adults and for which
the safety for children was unknown.”218 The drugs tested were failed cancer drugs that
had severe side effects including rashes, vomiting, sharp drops in infection-fighting
blood cells, and death.219 Hence, yet again, healthy minority children were subjected to
medical research studies that lead to disability and death.
The dangers of participation in these studies for healthy children are best
illustrated by an Illinois study of Dapsone, a drug to prevent AIDS-related
pneumonia.220 “Researchers reported some children had to be taken off the drug
because of ‘serious toxicity,’ others developed rashes, and the rates of death and blood
toxicity were significantly higher in children who took the medicine daily, rather than
weekly.”221 The researchers noted that for the period of the study “[a]t least 10
children died from a variety of causes, including four from blood poisoning, and
researchers said they were unable to determine a safe, useful dosage. They said the
deaths didn’t appear to be ‘directly attributable’ to Dapsone but nonetheless were
‘disturbing.’”222
Finally, the HIV/AIDS drug studies continued even after 1990 when
Azidothymidine, better known as AZT, was shown to be an effective treatment for
HIV/AIDS without severe side effects.223 Children who participated in these
HIV/AIDS drug tests were prohibited from taking AZT in order to determine if the
new drugs were effective. This would have been acceptable if each foster child
enrolled in the study had been tested to see if AZT was not an option. If AZT was not
212
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an option for treatment, then and only then, would it be just for the children to
participate in medical research.
Advocates of the research have argued that the inclusion of these children in the
research benefited the children by increasing their access to new and effective
HIV/AIDS drugs.224 However, it is unclear how many children participating in the
study actually needed access to HIV/AIDS drugs, because none of the children were
actually tested for HIV/AIDS. .225 Furthermore, as discussed in Section IV.B.1, the
presumption that participation in medical research studies, particularly Phase I and II
studies, provides access to life-saving treatment is a therapeutic misconception. These
phases only test safety and toxicity.226 Hence, participation in medical research studies
at these stages does not provide the participant with a direct health benefit, especially
when compared to the dangers of the research.
Furthermore, economically disadvantaged minority children who have HIV/AIDS
and participated in the early phases of HIV/AIDS drug studies were not provided with
access to the drugs that were approved in the United States and abroad.227 In fact,
many of these children with HIV/AIDS still do not have access to HIV/AIDS drugs
because they cannot afford them.228 Harms caused by the inclusion doctrine are not
just limited to the United States. Researchers have used this doctrine to grant
economically disadvantaged minority children in developing countries a ‘fair
opportunity’ to participate in medical research studies that have not increased access to
treatment and have resulted in serious harm and death.229
2. Inclusion Theory Internationally
In 2008, researchers conducted vaccine trials on infants in Santiago del Estero, a
province of Argentina.230 The trials were testing Synflorix, a new vaccine, “to prevent
pneumonia, ear infections, and other pneumococcal diseases,” which would compete
against a vaccine already approved and proven safe and effective.231 That year, seven
babies died from Synflorix, and a total of fourteen children died during the testing.232
Because there was no evidence that children in this region disproportionately suffered
from ailments Synflorix was intended to treat, there was no reason to use these
children for the study other than their compromised position and easy manipulability.
Over a thirty-month period, children in New Delhi were enrolled in medical
research studies testing a wide range of drugs “from high blood pressure to chronic
focal encephalitis, a brain inflammation that causes epileptic seizures and other
neurological problems.”233 Approximately, two-thirds of the children studied were less
than one year old, of which forty-nine died as a result of participation in these medical
research studies.234 Again there was no evidence that children in this region
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disproportionately suffered from these conditions, so there was no reason to use them
for the study other than their compromised position and easy manipulability.
In 1996, researchers traveled to Kano, Nigeria to test Trovan, an antibiotic, on
pediatric patients suffering from bacterial meningitis.235 The objective of the study was
to determine whether an oral version of Trovan, one of the United States’ best selling
antibiotics, worked better than ceftriaxone, a fast-acting antibiotic already proven
effective for treating bacterial meningitis.236 Two hundred children waiting for
ceftriaxone, the proven therapy, participated in the study.237 Instead of receiving
ceftriaxone, some children were given an oral version of Trovan, which had never
been tested before in humans.238 Others were given a dose of ceftriaxone that was
below the dosage prescribed to treat bacterial meningitis.239 Eleven children died
unnecessarily.240 Advocates of the research and the inclusion doctrine argued that the
research did not violate the justice principle because it provided access to medicine as
“a ‘massive epidemic [of bacterial meningitis] killing more than 11,000 people’”
spread across Nigeria.241 However, this study inequitably targeted Nigerian children in
violation of the justice principle.
Comparable to the HIV/AIDS drug studies discussed above, the antibiotic medical
research studies violated the order of preference for selecting research subjects because
children were used to test oral Trovan before being proven safe in humans.242 Second,
the study was conducted during an epidemic although there was already a proven
treatment.243 Thus, it can be argued that the children were selected because the
bacterial meningitis was an epidemic, which put the children in a compromised
position to participate in medical research studies that promised potentially life-saving
treatment.244
Third, the study caused harm because it prevented all participants from obtaining
the proven therapy. Even though some children were given ceftriaxone, the dosage
was below that needed to treat bacterial meningitis.245 Moreover, the oral form of
Trovan was never used outside of the study and three years later the United States
limited the use of the non-oral form of Trovan because it was linked to liver damage
and deaths.246
As evidenced by the aforementioned studies, the inclusion doctrine has been used
as a justification for ignoring the requirements of the justice principle to target
economically disadvantaged minority children for participation in medical research.
The time has come to redefine justice, to measure the impact of research on vulnerable
populations, and to implement a new regulatory structure for approving medical
235
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research studies conducted using children, particularly economically disadvantaged
minority children.
V. JUSTICE AS EQUITY IN PARTICIPATION: USING THE VULNERABILITY
AND EQUITY IMPACT ASSESSMENT TO STOP TARGETING
Although arguments for inclusion were based on altruistic notions of providing
everyone with a ‘fair opportunity’ to participate in medical studies, some researchers
have used this interpretation of the justice principle to target economically
disadvantaged minority children. As a result, numerous children have died or been
seriously harmed. Consequently, the justice principle must be redefined in a manner
that ensures equity and fairness in the use of all children.
I suggest that justice should be defined as “equity in participation,” which
demands that economically disadvantaged minority children are only selected for
medical research studies if their participation allows them to reach their highest
attainable standard of health, by granting them continued access to health care and/or
the alleviation of some burdens placed on them. This is accomplished when the
medical research study focuses on conditions that are a priority to this population,
eliminates some social disadvantage, and does not place additional burdens on them.
To ensure that there is equity in participation in medical research studies using
economically disadvantaged minority children, I propose the use of the Vulnerability
and Equity Impact Assessment (VEIA), which I created based on the Health Equity
Impact Assessment (HEIA) tool.247 Under the VEIA, the researcher must complete an
introspective summary of their research that includes the study’s purpose, the affected
population, whether the research is a priority to the affected population, and any
disparities (age, race, or class) in the treatment of the condition. Researchers must also
identify the social disadvantage of, and burdens on, these vulnerable children being
considered for participation, the adverse impacts from participating in the study, and
how participation will outweigh these burdens and adverse impacts. If researchers
determine that because of their status (age, social class, or race) children are easily
manipulated, in a compromised position, or overburdened, then the researchers cannot
use the children as research subjects.
Using the VEIA, a newly created Board of Children (Board) would be responsible
for approving all medical research studies that include children and are seeking federal
funding or drug approval in the United States. The completed tool should be posted on
ClinicalTrials.gov and used by the Board to determine if the researcher is targeting
economically disadvantaged minority children in violation of the redefined justice
principle. Redefining justice to mean equity in participation, implementing the VEIA,
and creating a Board to review all medical research studies using children will provide
the analytical and regulatory framework currently missing from the IRB process.
A. JUSTICE AS EQUITY IN PARTICIPATION
To put an end to targeting, there must be a shift in the interpretation of the justice
principle from the inclusion doctrine to the “equity in participation” doctrine, which I
created based on equity in health definitions.248 The justice principle should include a
definition of equity, which requires that everyone have a fair opportunity to attain his
247

HABER, supra note 11 (explaining the Health Equity Impact Assessment).
P. Braveman & S. Gruskin, Defining Equity in Health, 57 J. EPIDEMIOLOGY CMTY. HEALTH 254,
256 (2003).
248

AMERICAN JOURNAL OF LAW & MEDICINE

824

or her full health potential,249 instead of having a fair opportunity to participate in
medical research studies.
Specifically, equity in participation will require researchers to use the order of
preference to select research subjects and prevent them from overburdening
economically disadvantaged minority children by further restricting their limited
access to health care. Hence, I propose that the justice principle be defined as equity in
participation based on Drs. Braveman and Gruskin’s definition of equity in health.
Braverman and Gruskin’s definition states that, “[e]quity in health is an ethical
value, inherently normative, [and] grounded in the ethical principle of distributive
justice.”250 Equity in health has been used to “guide operationalization and
measurement” of the right to the “highest attainable standard of health as indicated by
health status of the most socially advantaged group.”251 According to Drs. Braveman
and Griskin, equity in health is “the absence of systematic disparities in health (or in
the major social determinants of health) between [race and class] social groups who
have different levels of underlying social advantage/disadvantage—that is different
positions in a social hierarchy.”252 “Inequities in health systematically put groups of
people who are already socially disadvantaged (for example, by virtue of being
economically disadvantaged, female, and/or members of a disenfranchised racial,
ethnic, or religious group) at further disadvantage with respect to their health.”253 “The
concept of health equity focuses attention on the distribution of resources and other
processes that drive a particular kind of health inequity.”254 “A health disparity
between more and less advantaged population groups constitutes an inequity . . .
because the disparity is strongly associated with unjust social structures,” which “put
disadvantaged groups at generally increased risk of ill health and also generally
compound the social and economic consequences of ill health.”255
Not only does equity define what is fair, it imposes duties. According to the
government of Ontario, equity in health requires the state to reduce “systemic barriers
to equitable access to high quality health care for all; [to address] the specific health
needs of people all along the social gradient, including the most health disadvantaged
populations; and [to ensure] that the ways in which health services are provided and
organized contributes to reducing overall health disparities.”256 Health equity also
imposes a duty on the state to work to “reduce or eliminate socially structured health
inequalities and differential health outcomes.”257
Using these theories of equity and duty as a guide, I suggest that the justice
principle be defined in terms of equity in participation. In particular, equity in
participation should mean that vulnerable populations, such as economically
disadvantaged minority children, can only serve as research subjects when the medical
research study will allow the participants to reach their highest attainable standard of
health. This is accomplished when the medical research focuses on conditions that are
a priority to the vulnerable population, eliminates some form of social disadvantage,
249
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and does not add burdens to the vulnerable population. Even if the study fulfills these
requirements, researchers should not use these populations if they are in a
compromised position and participation can exacerbate the problems that these
vulnerable populations experience because of their race, class, and age.
For example, institutionalized class and racial biases predict differential access to
essential goods, such as health care, which cause disparities in disease, disability, and
death.258 Burdened by an increase in disease, disability, and death, these children are a
panacea for researchers investigating treatment and obtaining generalizable scientific
knowledge, not usually relevant to their health condition.259 Powerless these children
are invited to participate in medical research studies that provide minimal access to
health care and will not alleviate their increased rate of disease, disability, or death.260
By doing this, researchers perpetuate the continued unequal distribution of access to
health care when they use those without access for studies not even focused on issues
suffered by their children.
Under the equity in participation doctrine, researchers would not be able to take
advantage of the fact that economically disadvantaged minority children lack access to
health care, as a means to enroll them in medical research studies. The researchers
could only use them as subjects if the study focused on issues that are a priority to
economically disadvantaged minority children and eliminated some social
disadvantage, like lack of access to health care. To measure whether the equity in
participation requirement is being met, I suggest that researchers be required to use
VEIA.261
B. HEALTH IMPACT ASSESSMENT TOOLS
In 1970, the United States became the first country to require impact assessments
to predict and assess the impact of policies on environmental health.262 Since then,
several countries (Germany, Switzerland, and Canada) and international organizations
(World Health Organization and the European Union) have required Environmental
Impact Assessments to be completed in response to “highways, train lines, airports,
industrial plants, waste disposal facilities, and many other development projects.”263
Since 1999, many countries, such as Germany, Switzerland, the Netherlands,
Australia, New Zealand, Canada, and the United States have adopted this tool for use
in the health field to avoid or minimize negative impacts on health.264 Impact
assessment tools put the burden on those researchers completing the tool to show that
their actions will not negatively impact the health of the population.
The Health Impact Assessment (HIA) is “a combination of procedures, methods
and tools by which a policy, programme or project may be judged as to its potential
effects on the health of a population, and the distribution of those effects within the
population.”265 There are two main functions of the HIA: 1) “to support policy making
258
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in choosing between options” and 2) to predict “the future consequences” of
implementing different policy options.266 There are six key stages in using a HIA:
“screening, scoping, data collection, impact appraisal, reporting/recommendations, and
monitoring/evaluation.”267 By using the HIA, policymakers can adopt the most
beneficial policy for the population’s health. Attaining equity in health can be one of
the priorities in completing an HIA. However, equity is not the main focus of the
HIA.268 Although the HIA can determine if the policy will have different impacts on
different social groups, the process does not provide information concerning whether
these differential impacts are a result of unfair and biased policies.269
Consequently, the HEIA was created to ensure that assessments about a policy’s
impact would include an evaluation of fairness and equity as well as root causes of
inequities.270 The HEIA identifies the root causes of health inequity, such as wealth,
income, knowledge, and power imbalances.271 The World Health Organization’s
Commission on the Social Determinants of Health has recommended the use of the
HEIA in all global, national, and local policy making.272 New Zealand, Australia,
Canada, the United Kingdom, the United States, and other countries currently use the
HEIA.273 There are five purposes of a HEIA:
x

Help identify potential health impacts (positive or negative) of a plan, policy or
program on vulnerable or disadvantaged groups within the general population.

x

Help develop recommendations as to what adjustments to the initiative might
mitigate negative impacts as well as maximize positive impacts on the health of
vulnerable or disadvantaged groups.

x

Embed equity across an organization’s existing and prospective decisionmaking models, so that it becomes a core value and one criterion to be weighed
in all decisions.

x

Support equity-based improvement in program/service design: ‘How does this
program need to be adjusted to meet the needs of specific populations?’ ‘Could
this program benefit some, but not others?’

x

Raise awareness about health equity as a catalyst for change throughout the
organization, so planners and managers develop ‘stretch goals’: How can we
include more people in this program, especially those often missed? What
barriers do we have to look for? Are we as effective as we could be, especially
those with the greatest and most complex health needs?274

When completing a HEIA, the following five steps must be completed:
Screening:
Determine if the initiative requires a HEIA. If the initiative has the potential to impact the
health of vulnerable or disadvantaged groups, HEIA is applicable. It is desirable that all
initiatives be screened.
Scoping:
Identify affected populations or groups and predict key impacts (positive or negative) on
those groups. Consider a wide range of vulnerable or disadvantaged groups to avoid
overlooking unexpected or unintended consequences of an initiative.
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Impact Assessment:
Use available data/evidence to prospectively assess the impacts on vulnerable or
disadvantaged groups in relation to the broader target population. It is both useful and
important to consider a broader range of evidence including consultation findings and grey
literature (including project or program reports, informal practice guidelines, recommended
or promising practices). These sources of evidence should be weighed based on their
strength and quality.
Where there is very limited data/evidence available, note the lack of evidence in the
assessment or, where possible, implement other strategies to gather evidence. Strategies
could include conducting surveys, focus groups, or consultation with experts or members
of the affected groups where time permits.
Mitigation Strategy
Develop evidence-based recommendations to minimize or eliminate negative impacts and
maximize positive impacts on vulnerable or disadvantaged groups. These
recommendations comprise your mitigation strategy. Uptake of these recommendations in
the roll out of the initiative will help to ensure that the initiative contributes to equity and
does not perpetuate or widen existing health disparities. Where possible, recommendations
should be informed by diverse members of the affected communities.
Monitoring and Evaluation
Determine how the rollout of the initiative will be monitored to determine its impacts on
vulnerable or disadvantaged groups in comparison to other subpopulations or the broader
target population. The resulting data will enhance the overall evidence base for equitybased interventions and can be fed back into the planning, policy or program development
process.275

Once these steps have been completed, the organization must decide whether or
not to implement the policy.276
A Racial Equity Impact Assessment (REIA) tool has also been created to identify
the impacts of policies on racial and ethnic groups.277 Governments in Seattle,
Washington, St. Paul, Minnesota, and the United Kingdom have adopted the REIA.278
Although the primary focus of the HEIA and REIA are to reduce health inequities, I
believe that with some modification these tools can be used to create a tool to address
inequities in medical research, such as the targeting of economically disadvantaged
minority children.
C. VULNERABILITY AND EQUITY IMPACT ASSESSMENT TOOL
Based in part on the HEIA and the REIA, the VEIA should be used to assess
whether a proposed research study is targeting vulnerable populations for use in
medical research in violation of the redefined justice principle. The VEIA would
require researchers to review the “social, racial, sexual, and cultural biases
institutionalized in society” that place a class of people in a compromised position and
easily manipulated into participation in medical research studies. The VEIA will
require researchers to identify these institutionalized biases and determine whether the
problems from these biases bar vulnerable populations from participating in medical
research studies because it keeps them from attaining their highest standard of health.
In this article I focus on how the VEIA can be used to protect disadvantaged children;
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however, the VEIA can be used to protect all children and other vulnerable
populations.279
1. The VEIA
First, the researcher must screen the research proposal to identify the purpose of
the research, what the research seeks to accomplish, and whether the research has the
potential to negatively affect economically disadvantaged minority children. If the
research has a potential to burden this population or prevent them from attaining their
highest standard of health, the researcher must discuss in their research proposal, why
they feel that the use of these vulnerable children is necessary. Additionally, the
researcher must discuss whether the research is a priority for the children. This review
can be incorporated into the current requirement of showing that research will add to
generalizable scientific knowledge.280
In order to answer these questions, the researcher must engage economically
disadvantaged minority children or someone who represents their interests, such as
Marian Wright Edelman, the President and Founder of the Children’s Defense Fund,281
or community leaders who focus on children’s health issues. This screening dovetails
with procedures used by researchers when they conduct international research to
ensure that research is culturally competent.282 Once this introspective review, or
screening, has occurred and is noted in the research proposal, then the researcher must
complete the scoping, impact assessment, and mitigation strategy steps.
To complete the scoping step, the researcher must answer the following questions:
1.
2.

What populations are most affected by the condition being studied?
Even if economically disadvantaged minority children are most affected
by the condition, are there other less vulnerable populations that can be
used for the research?

If economically disadvantaged minority children are most affected by the
condition, then the researcher must assess whether the impacts on this population are
negative or positive. To complete the impact assessment step, a researcher must use all
available data, such as empirical research studies. If there is limited data available,
then the researcher should collect data by “conducting surveys, focus groups, or
consultation[s] with experts or members of the affected groups where time permits.”283
The evidence should be used to answer the following questions:
1.

Disparities:
a. Are there race, class, and/or age disparities in the number of people
who suffer from the condition?
b. Are there race and/or class disparities in the number of people who
survive the condition?

279
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“What quantitative and qualitative evidence of inequality exists?” 284
Which racial/ethnic groups are currently most advantaged and most
disadvantaged by the issues this research seeks to address?
e. Which socioeconomic groups are currently most advantaged and
most disadvantaged by the issues this research seeks to address?
f. Which age groups are currently most advantaged and most
disadvantaged by the issues this research seeks to address?
g. How are groups affected differently?
h. What evidence is missing or needed?
i. Will the research exacerbate these disparities?
j. Will the research address these disparities?
Burdens:
a. What are the burdens on economically disadvantaged minority
children who are potential research subjects?
b. Will participation in medical research studies exacerbate these
burdens?
c. What are the root causes of the burdens, such as racial and class
biases?
d. Will the research address these root causes?
Adverse Impacts:
a. What potential adverse impacts or unintended consequences could
result from participation in this research?
b. Will the impacts or unintended consequences further burden
economically disadvantaged minority children?
c. How could adverse impacts be prevented or minimized?
d. Can the research provide a solution to address the burdens faced by
economically disadvantaged minority children?
“Equitable Impacts:
a. What positive impacts on equality and inclusion, if any, could result
from this proposal?
b. Which racial/ethnic groups could benefit?
c. Which socioeconomic groups could benefit?
d. Which age groups could benefit?
e. Are there further ways to maximize equitable opportunities and
impacts?” 285
c.
d.

2.

3.

4.

Using the answers from these questions, the researcher must provide an evidencebased determination of whether economically disadvantaged minority children should
be used as subjects because there are no additional burdens and/or the research will
eliminate burdens for this population. If the researcher decides to use economically
disadvantaged minority children as research subjects even though there is a possibility
for targeting, the researcher must develop a mitigation strategy that will minimize or
eliminate the institutionalized biases that prevent economically disadvantaged minority
children from equal access to essential goods such as food, education, and health care.
If there is a mitigation strategy, the researcher must monitor the strategy throughout
the study. Additionally, once the research is conducted, the researcher must monitor
the actual impact the research has on economically disadvantaged minority children in
284
285
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comparison to advantaged groups. One way to monitor the impact is to determine
whether there is a decrease in survival rate disparities between economically
disadvantaged minority children and the advantaged population once the research is
conducted.
2. Applying the VEIA
If researchers are required to apply the VEIA, many of the studies that targeted
vulnerable populations in violation of the law would never have been funded.
For example, if the researchers who used African American and Latino foster
children to test HIV/AIDS drugs, completed a VEIA, the tool would have shown the
research violated the justice principle. First, the researchers would have been required
to screen the research to identify the purpose of the research, what the research sought
to accomplish, and whether the research had the potential to affect economically
disadvantaged minority children.
Clearly, the screening would have shown that the medical research study had the
potential to impact economically disadvantaged minority children if they were used as
subjects, and it is unclear why healthy children had to be used to test HIV/AIDS drugs.
Furthermore, there is no evidence that this research was a priority to healthy
vulnerable children in foster care. If researchers were able to show that HIV/AIDS was
a health priority, the research would still be prohibited under the scoping step. There is
no evidence that at the time of the research, economically disadvantaged African
American and Latino children were the group most affected by HIV/AIDS. Therefore,
other children should have been used. Moreover, the impact assessment would have
shown that the research was too dangerous to conduct on this population because the
drugs had severe side effects for otherwise healthy children.
Additionally, the researchers discussed in Section IV.C.2 who traveled to Nigeria
to test Trovan on pediatric patients suffering from bacterial meningitis would not have
been able to show that their study complied with the justice principle using the
VEIA.286 If researchers had screened the study, VEIA would have shown that the
Nigerian children, who were vulnerable, would be negatively impacted by the
research. The scoping step would have shown that other children were also affected by
bacterial meningitis. Because these other groups were not in the middle of an
epidemic, they would have been better subjects.
Furthermore, VEIA would have shown that the negative impact of the research
outweighed any benefits from participation in the medical research study and could not
be mitigated. First, there was already a proven therapy for the disease that children
participating in the study were barred from taking.287 Second, the children could have
died, an unreasonable impact that cannot be mitigated by any benefit. Thus, the
researchers never should have used economically disadvantaged minority children.
These are just a couple of examples of how using the VEIA will protect
economically disadvantaged minority children from being targeted. However, the
adoption of justice as equity in participation and implementation of the VEIA will not
put an end to targeting without changes to the current regulatory structure governing
medical research studies using children.
D. A NEW REGULATORY STRUCTURE
286
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In the past, OHRP and individual IRBs have been responsible for ascertaining
whether the selection of economically disadvantaged minority children violated the
justice principle. The examples discussed in Section I.V.C. suggest that neither OHRP,
nor individual IRBs have been successful in accomplishing this task. Thus, I suggest
the creation of a federal Human Research Protection Review Board for Children
(Board for Children or the Board) using the authority granted by the Common Rule to
review medical research studies otherwise unapprovable288 and the creation of an
International Board of Children (IBOC) to review medical research studies using the
authority granted by the w.
The Board for Children and the IBOC would be in charge of determining whether
domestic and international medical research studies involving children were ethically
based upon the redefined justice principle.289 Before a medical research study was
conducted the Board of Children and/or the IBOC would be required to review the
research proposal to evaluate whether the research targets economically disadvantaged
minority children for studies in violation of the redefined justice principle.
To accomplish this task for research governed by the Common Rule, the Board for
Children needs to have adequate community participation and specific requirements
for the approval of research. The Board for Children must include at least two
members of each group identified as a vulnerable population in the Common Rule.
The Board for Children must also consist of at least two physicians that conduct
research. However, these physicians cannot be from institutions that have been cited
for violations by the OHRP. Finally, the Board for Children should include three
bioethicists, two child advocates, and two government employees.
The Board must review the VEIA for all medical research studies using children
governed by the Common Rule to ensure the studies comply with the redefined justice
principle. This review must occur before the researcher submits the proposal for
funding and drug approval. The Board would be responsible for reviewing the VEIA
for each research proposal to make sure that the study was not targeting economically
disadvantaged minority children for medical research studies.290 If the VEIA shows
that there is no targeting and the study was necessary and safe, then the Board should
approve the study and post the VEIA on ClinicalTrials.gov.
The IBOC should review proposals for medical research studies using children
that are governed by the ICH-GCP. Using the VEIA to enforce the ICH-GCP, the
IBOC would review all proposals for pediatric studies to ensure they comply with the
redefined justice principle. The membership of the IBOC would include members of
each group identified as a vulnerable population group in the ICH-GP. The IBOC
would also consist of at least two physicians that conduct research. However, these
physicians cannot be private contractors or from organizations that have conducted
illegal and unethical research in the past. Finally, the IBOC should include three
bioethicists, two child advocates, and three government employees (one from each
regulatory authority in the EU, Japan, and the United States). The IBOC’s review
would be the similar to the Board of Children’s review. The review would take place
before the researcher submits the proposal for drug approval.
Specifically, if a researcher planned to seek drug approval under the ICH-GCP,
the researcher would need to complete a VEIA and submit it to the IBOC before
288
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conducting studies on children. The IBOC would review the VEIA for each research
proposal and ensure that the study was not unfairly targeting economically
disadvantaged minority children for medical research.291 If the VEIA shows that there
is no targeting and the study was necessary and safe, then the IBOC should approve
the study.
The creation of these Boards is just the beginning of the structural changes that
need to be made to regulate pediatric medical research. Additionally, new penalties
need to be imposed if a researcher and/or an institution violates the justice principle.
Currently, OHRP just issues letters and suspends researchers from federally-funded
research. Violations of the justice principle should also result in fines, loss of federal
funding, and denial of drug approval. Researchers that violate the requirements should
also face criminal fines.292 Furthermore, victims of research conducted in violation of
the justice principle should be granted a private right of action against the institution
and the researcher.
As more and more pediatric research is conducted overseas and outside of the
public eye, it is imperative that the U.S. government, in cooperation with other
governments, begins to aggressively enforce laws to protect all children, especially
economically disadvantaged minority children, from being targeted for participation in
medical research. Otherwise, these children will continue to suffer long-term disability
or death.
VI. CONCLUSION
Children are vulnerable beings who we try to protect by limiting their access to
alcohol, guns, and employment.293 Moreover, we limit their autonomy because,
although we believe children are sacred, we question their decision-making capacity.
We impose these limitations seemingly to protect children because they are vulnerable
and susceptible to exploitation.294 Yet, some researchers willingly exploit children by
targeting them to participate in medical research studies because it has the potential to
benefit society.
Some bioethicists and researchers argue that all children are morally required to
participate in medical research studies to provide a benefit to the society that benefits
them. However, for economically disadvantaged minority children who lack access to
essential goods, one must ask what benefit are the children receiving that they need to
pay back? For many countries, including the United States, do not provide, nor
guarantee a right to food, education, housing or health care for these children. So what
duty do these children have to society? This is not a new question. As Patricia King
noted, “American bioethics has tended to focus its attention on ethical issues
associated with scientific and medical advances without recognizing that these
developments occur in a social context that must be taken into account if the ethical
issues are to be adequately addressed.”295
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Therefore, the time has come to put an end to this exploitation by enforcing the
justice principle and prevent the targeting of all children, but especially economically
disadvantaged minority children, from participation in medical research studies. This
will only happen if the justice principle stands for more than inclusion. The justice
principle must be a measurable standard that ensures fairness, equity, and the right of
children to reach their full health potential without interference. Otherwise, children
will continue to be sacrificed for the benefit of an unworthy society.

